StreetInsider.com News Articles

United Therapeutics Corp. (UTHR) PT Raised to $850 at Cantor Fitzgerald

Mon, 26 Oct 2026 10:19:53 -0400

Cantor Fitzgerald analyst Olivia Brayer raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $850.00 (from $700.00) while maintaining a Hold rating.

Form 4 UNITED THERAPEUTICS Corp For: Oct 22 Filed by: ROTHBLATT MARTINE A

Fri, 23 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261023/27228309.html

Form 4 UNITED THERAPEUTICS Corp For: Oct 21 Filed by: ROTHBLATT MARTINE A

Thu, 22 Oct 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20261022/27223204.html

United Therapeutics Corp. (UTHR) PT Lowered to $697 at RBC Capital

Thu, 22 Oct 2026 07:14:16 -0400

RBC Capital analyst Lisa Walter lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $697.00 (from $708.00) while maintaining a Outperform rating.

United Therapeutics authorizes $2 billion share repurchase program

Thu, 22 Oct 2026 07:00:35 -0400

United Therapeutics Corporation (Nasdaq: UTHR) announced that its Board of Directors has authorized a new share repurchase program of up to $2 billion of the company's common stock, available through October 21, 2027.

The company may conduct repurchases through accelerated share repurchase programs, open market transactions, privately negotiated transactions, or other means. The program does not require a minimum number of shares to be purchased, and repurchases are subject to the company's discretion based on alternative uses of capital and market conditions. United Therapeutics may commence or suspend purchases at any time without prior notice.

United Therapeutics also disclosed an ongoing accelerated

Form 8-K UNITED THERAPEUTICS Corp For: Oct 21

Thu, 22 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261022/27218778.html

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

Thu, 22 Oct 2026 07:00:00 -0400

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors has authorized a new share repurchase program for up to $2 billion of the company’s common stock, available through October 21, 2027.

“We have the balance sheet and free cash flow to fund our long-term ambitions and the confidence to act decisively when our own shares represent a compelling investment,” said James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics. “This authorization is a clear reflection of our deep conviction in

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

Thu, 22 Oct 2026 07:00:00 -0400

Form 4 UNITED THERAPEUTICS Corp For: Oct 20 Filed by: ROTHBLATT MARTINE A

Wed, 21 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261021/27216935.html

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

Wed, 21 Oct 2026 07:00:00 -0400

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will be issued on Wednesday, November 4, 2026, at approximately 6:30 a.m. Eastern Time.

United Therapeutics will host a public webcast on Wednesday, November 4, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location.

About United Therapeutics

Founded by CEO Martine Rothblatt to

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

Wed, 21 Oct 2026 07:00:00 -0400

About United Therapeutics

Founded by CEO Martine Rothblatt to

Form 4 UNITED THERAPEUTICS Corp For: Oct 19 Filed by: ROTHBLATT MARTINE A

Tue, 20 Oct 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20261020/27210935.html

United Therapeutics opens third xenograft production facility in Houston

Tue, 20 Oct 2026 07:01:02 -0400

United Therapeutics Corporation (Nasdaq: UTHR) has opened its third Designated Pathogen-Free (DPF) xenograft production facility in Houston, Texas, according to a company statement dated October 20, 2026.

The facility, named the Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, is designed to manufacture xenokidneys and xenohearts. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024, and its second, the Thomas E. Starzl Xenograft Production Facility, in Stewartville, Minn. on August 12, 2026. The two newer facilities are intended to support commercial-scale production if the company's xeno-organ products receive regulatory approval.

Each facility operates within a

United Therapeutics opens third xenograft production facility in Houston

Tue, 20 Oct 2026 07:01:02 -0400

Each facility operates within a

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

Tue, 20 Oct 2026 07:00:00 -0400

Named for Dr. Bartley P. Griffith and Dr. Robert A. Montgomery, pioneers in xenotransplantation, the biosecure facility is purpose-built to manufacture United Therapeutics’ xenokidneys and xenohearts for its rapidly advancing xeno-organ manufacturing program

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas.

United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

Tue, 20 Oct 2026 07:00:00 -0400

United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. The company

United Therapeutics Corp. (UTHR) PT Raised to $717 at Raymond James

Tue, 20 Oct 2026 06:35:31 -0400

Raymond James analyst Tiago Fauth raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $717.00 (from $685.00) while maintaining a Outperform rating.

Form 4 UNITED THERAPEUTICS Corp For: Oct 16 Filed by: ROTHBLATT MARTINE A

Mon, 19 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261019/27204363.html

FDA clears United Therapeutics to begin treprostinil SMI trial

Mon, 19 Oct 2026 07:03:34 -0400

United Therapeutics Corporation (Nasdaq: UTHR) announced that the U.S. Food and Drug Administration has cleared the company to proceed with its SUMMIT clinical trial, a phase 2 study evaluating treprostinil delivered via a soft mist inhaler (SMI) in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).

The 16-week, double-blind study will enroll approximately 40 patients and assess the safety and tolerability of treprostinil SMI. Secondary endpoints will measure exercise capacity and NT-proBNP levels, a biomarker associated with heart failure. Patients completing the study may enroll in an open-label extension to evaluate long-term outcomes.

If the phase 2 study produces

FDA clears United Therapeutics to begin treprostinil SMI trial

Mon, 19 Oct 2026 07:03:34 -0400

If the phase 2 study produces

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

Mon, 19 Oct 2026 07:00:00 -0400

The development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles

A soft mist formulation may be beneficial for patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), who are susceptible to cough and bronchospasm from inhaled therapies

Treprostinil SMI has the potential to be the first FDA-approved therapy specifically indicated for PH-COPD

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted

United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

Mon, 19 Oct 2026 07:00:00 -0400

The development of a soft mist inhaler (SMI) represents a further advancement of treprostinil delivery devices to potentially address a wider range of patient tolerability profiles

Treprostinil SMI has the potential to be the first FDA-approved therapy specifically indicated for PH-COPD

Increasing unusual option volume: UTHR MXEF DVA LSCC IMVT CZR BBD

Mon, 19 Oct 2026 05:08:44 -0400

Increasing unusual option volume: UTHR MXEF DVA LSCC IMVT CZR BBD

Form 4 UNITED THERAPEUTICS Corp For: Oct 15 Filed by: ROTHBLATT MARTINE A

Fri, 16 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261016/27198336.html

Form 4 UNITED THERAPEUTICS Corp For: Oct 15 Filed by: MAHON PAUL A

Fri, 16 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261016/27198320.html